BioTime To Present at Regen Med Investor Day March 26 in New York ALAMEDA, Calif.--(BUSINESS WIRE)

To Present at Regen Med Investor Day March 26 in New York

ALAMEDA, Calif.--(BUSINESS WIRE)--March 25, 2014--BioTime, Inc. (NYSE

MKT: BTX), a biotechnology company that develops and markets products in

the field of regenerative medicine, today announced that Chief Executive

Officer Michael D. West, PhD will present at the 2nd Annual

Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York

Organized by the Alliance for Regenerative Medicine (ARM) in partnership

with leading financial firms Maxim Group and Piper Jaffray, this one-day

investor conference focuses exclusively on the regenerative medicine and

advanced therapies sector. The event includes clinical and commercial

experts who will be on-hand to address specific questions regarding the

outlook for the industry, as well as offer insight into how regenerative

medicine products could impact the standard of care in key therapeutic

areas. The program will include talks by key opinion leaders in the

industry, life science investment experts and analysts as well as

presentations by more than 30 leading companies from across the globe.

A live-streaming webcast of all panels and company presentations will be

available at: http://www.arminvestorday.com/webcast and will be

published on the event's website shortly after the conference. The

presentation will also be made available on BioTime's website at www.biotimeinc.com.

Attendance at this event is for credentialed investors and members of

the media only. If you are interested in attending, please contact Laura

Parsons at lparsons@alliancerm.org. Please visit http://www.arminvestorday.com

for more information.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based

multi-stakeholder advocacy organization that promotes legislative,

regulatory and reimbursement initiatives necessary to facilitate access

to life-giving advances in regenerative medicine and advanced therapies.

ARM also works to increase public understanding of the field and its

potential to transform human healthcare, providing business development

and investor outreach services to support the growth of its member

companies and research organizations. Prior to the formation of ARM in

2009, there was no advocacy organization operating in Washington, DC to

specifically represent the interests of the companies, research

institutions, investors and patient groups that comprise the entire

regenerative medicine community. Today ARM has more than 150 members and

is the leading global advocacy organization in this field. To learn more

about ARM or to become a member, visit www.alliancerm.org.

BioTime is a biotechnology company engaged in research and product

development in the field of regenerative medicine. Regenerative medicine

refers to therapies based on stem cell technology that are designed to

rebuild cell and tissue function lost due to degenerative disease or

injury. BioTime's focus is on pluripotent stem cell technology based on

human embryonic stem ("hES") cells and induced pluripotent stem ("iPS")

cells. hES and iPS cells provide a means of manufacturing every cell

type in the human body and therefore show considerable promise for the

development of a number of new therapeutic products. BioTime's

therapeutic and research products include a wide array of proprietary PureStem

progenitors, HyStem hydrogels, culture media,

and differentiation kits. BioTime is developing Renevia (a HyStem

product) as a biocompatible, implantable hyaluronan and collagen-based

matrix for cell delivery in human clinical applications. In addition,

BioTime has developed Hextend , a blood plasma

volume expander for use in surgery, emergency trauma treatment and other

applications. Hextend is manufactured and

distributed in the U.S. by Hospira, Inc. and in South Korea by CJ

CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research,

therapeutic, and diagnostic use through its subsidiaries:

Asterias Biotherapeutics, Inc. is a new subsidiary which has acquired

the stem cell assets of Geron Corporation, including patents and other

intellectual property, biological materials, reagents and equipment for

the development of new therapeutic products for regenerative medicine.

OncoCyte Corporation is developing products and technologies to

diagnose and treat cancer.

Cell Cure Neurosciences Ltd. ("Cell Cure Neurosciences") is an

Israel-based biotechnology company focused on developing stem cell-based

therapies for retinal and neurological disorders, including the

development of retinal pigment epithelial cells for the treatment of

macular degeneration, and treatments for multiple sclerosis.

LifeMap Sciences, Inc. ("LifeMap Sciences") markets, sells and

distributes GeneCards , the leading human gene

database, as part of an integrated database suite that also includes the LifeMap

Discovery database of embryonic development, stem

cell research and regenerative medicine, and MalaCards, the human

ES Cell International Pte Ltd., a Singapore private limited company,

developed clinical and research grade hES cell lines and plans to market

those cell lines and other BioTime research products in over-seas

markets as part of BioTime's ESI BIO Division.

BioTime Asia, Limited, a Hong Kong company, may offer and sell

products for research use for BioTime's ESI BIO Division.

OrthoCyte Corporation is developing therapies to treat orthopedic

disorders, diseases and injuries.

ReCyte Therapeutics, Inc. is developing therapies to treat a variety

of cardiovascular and related ischemic disorders, as well as products

for research using cell reprogramming technology.

Additional information about BioTime can be found on the web at www.biotimeinc.com.

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results,

future growth in research, technology, clinical development, and

potential opportunities for BioTime and its subsidiaries, along with

other statements about the future expectations, beliefs, goals, plans,

or prospects expressed by management constitute forward-looking

statements. Any statements that are not historical fact (including, but

not limited to statements that contain words such as "will," "believes,"

"plans," "anticipates," "expects," "estimates") should also be

considered to be forward-looking statements. Forward-looking statements

involve risks and uncertainties, including, without limitation, risks